Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Catalyst Pharmaceuticals Inc    CPRX

CATALYST PHARMACEUTICALS INC (CPRX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Catalyst Pharmaceutical Partners, Inc. : Catalyst Receives Guidance From NASDAQ Regarding Minimum Bid Price Requirement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/27/2012 | 03:05pm CEST

CORAL GABLES, Fla., Dec. 27, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it received a Nasdaq Staff Deficiency Letter, dated December 24, 2012, indicating that the Company is not in compliance with the Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

The Nasdaq Listing Rules (the "Rules") require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price for the last 30 consecutive business days, the Company no longer meets this requirement. In light of the deficiency, the Rules also provide the Company with a grace period of 180 calendar days in which to regain compliance. If at any time during this grace period the bid price of the Company's security closes at or above $1.00 per share for a minimum of ten consecutive business days, the Nasdaq Stock Market will provide the Company with a written confirmation of compliance and the matter will be closed.

In the event the Company does not regain compliance with the Rule prior to the expiration of the grace period, the Company may be eligible for an additional 180-day grace period if at such time it meets the initial listing standards for listing on the Nasdaq Capital Market, with the exception of the bid price requirement.

The Company understands the Nasdaq requirements and believes it will be able to regain compliance with the Rules within the allotted grace period.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting orphan drug diseases and disorders of the central nervous system. Catalyst has three products in development, Firdapse™, which Catalyst plans to develop for commercialization in North America as a treatment for Lambert-Eaton Myasthenic Syndrome (LEMS), CPP-115, a GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin, which Catalyst plans to develop for the treatment of epilepsy (primarily infantile spasms) and CPP-109 (vigabatrin), which Catalyst hopes to develop for the treatment of Tourette's Disorder. For additional information about Catalyst, please visit www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether the Company will be able to regain compliance with the Rules within any applicable grace periods, whether any of the Company's product candidates will ever be approved for commercialization, and those factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: Patrick J. McEnany

         Catalyst Pharmaceutical Partners

         Chief Executive Officer

         (305) 529-2522

         [email protected]


         Melody Carey

         Rx Communications Group

         Co-President

         (917) 322-2571

         [email protected]
Source: Catalyst Pharmaceutical Partners, Inc.

News Provided by Acquire Media

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CATALYST PHARMACEUTICALS I
05/09CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
AQ
05/09CATALYST PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
AQ
05/09Catalyst Pharmaceuticals Announces First Quarter 2018 Financial Results and P..
GL
05/08CATALYST PHARMACEUTICALS : to Hold First Quarter Financial Results and Corporate..
AQ
05/02Catalyst Pharmaceuticals to Hold First Quarter Financial Results and Corporat..
GL
04/25CATALYST PHARMACEUTICALS : Announces Enrollment of First Patient in Phase 3 Tria..
AQ
04/24CATALYST PHARMACEUTICALS : Introduces New Corporate Website
AQ
04/20CATALYST PHARMACEUTICALS : Announces Enrollment of First Patient in Phase 3 Tria..
AQ
04/19CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
AQ
04/19Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Tri..
GL
More news
News from SeekingAlpha
05/10Catalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q1 2018 Resul.. 
05/09Catalyst Pharmaceutical EPS in-line 
04/30Institutional Investors Give Their Vote Of Confidence For Catalyst Pharmaceut.. 
04/19Enrollment underway in late-stage study of Catalyst Pharma's Firdapse in subt.. 
04/04Midday Gainers / Losers (4/4/2018) 
Financials ($)
Sales 2018 0,76 M
EBIT 2018 -35,2 M
Net income 2018 -34,7 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 464x
Capi. / Sales 2019 10,0x
Capitalization 353 M
Chart CATALYST PHARMACEUTICALS I
Duration : Period :
Catalyst Pharmaceuticals I Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Technical analysis trends CATALYST PHARMACEUTICALS I
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 7,33 $
Spread / Average Target 113%
EPS Revisions
Managers
NameTitle
Patrick J. McEnany Chairman, President & Chief Executive Officer
Steven R. Miller Chief Operating & Scientific Officer
Alicia Grande Chief Financial Officer, Treasurer & VP
Gary Ingenito Chief Medical Officer & Head-Regulatory Affairs
Philip H. Coelho Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CATALYST PHARMACEUTICALS INC-12.02%353
GILEAD SCIENCES-5.60%88 639
VERTEX PHARMACEUTICALS4.75%40 003
REGENERON PHARMACEUTICALS-21.45%31 288
GENMAB19.78%11 817
BEIGENE LTD (ADR)97.99%10 337